 Home > Active Ingredient News > Antitumor Therapy > The British Medicines and Healthcare Products Regulatory Agency (MHRA) supports Merck's MET inhibitor Teppetko in the treatment of non-small cell lung cancer (NSCLC)

The British Medicines and Healthcare Products Regulatory Agency (MHRA) supports Merck's MET inhibitor Teppetko in the treatment of non-small cell lung cancer (NSCLC)

 Last Update: 2021-10-20
 Source: Internet
 Author: User

Tags

adverse effects oxygen therapy

artemisinin cancer

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Recently, the British Medicines and Health Products Regulatory Agency (MHRA) has conditionally authorized Merck's MET inhibitor Teppetko (tepotinib) for the treatment of certain non-small cell lung cancer ( NSCLC ) patients
.

NSCLC

Non-small cell lung cancer is most common in older smokers and former smokers
.

Small lung tumors are usually asymptomatic, so most patients have locally advanced or metastatic disease at the time of diagnosis

Tepmetko's conditional marketing authorization provides treatment for adult patients with advanced NSCLC who carry a mesenchymal-epithelial transformation factor gene exon 14 (METex14) jumping mutation
.

MHRA's decision is based on the results of the Phase II VISION study, which evaluated the effectiveness of Teppetko monotherapy in patients with advanced or metastatic NSCLC with METex14 jumping mutations.
As of January 1, 2020, a total of 152 patients had received Teppetko.
For treatment, 99 patients were followed up for at least 9 months
.

The efficacy of Teppetko was evaluated in 146 patients.

The independent review of the study showed that the overall response rate (ORR) of the combined biopsy group was 45.

Figure 1.
Overall Response Rate (ORR)

Lung Cancer Fund will be Roy Paula Chadwick Castle, CEO, said: "We welcome the decision to approve MHRA tepotinib targeted therapy
of lung cancer may be an aggressive, difficult to treat cancer, so we have to provide as many treatment options for patients.

So that they can live with this disease for as long as possible

fund

Original source:

http:// href="http://" target="_blank" rel="noopener">http:// http:// Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.